Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339384 · ClinicalTrials.gov registry record · NA
Signatera Assessment in Early-Stage Endometrial Cancer
A NA study, sponsored by Natera.
- Not yet
- Registry status
- NA
- Development phase
- 1,010
- Enrollment target
NCT07339384: Clinical Trial NA study, sponsored by Natera.
NCT07339384 is a NA study that has not yet begun recruiting, run by Natera. The registered enrollment target is 1,010 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07339384, a NA study, has not yet begun recruiting, sponsored by Natera.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,010 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being
Primary Outcome
The primary objective of this study is to evaluate if recurrence free survival (RFS) is non-inferior among women with stage I high-intermediate risk endometrial cancer who are ctDNA-negative after surgery and managed with ctDNA-guided observation versus adjuvant VBT.
Interventions
- DEVICE Signatera Genome ultra-sensitive ctDNA blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2026-10 |
| Est. Completion | 2034-10 |
| Phase | NA |
What is known before NCT07339384 opens enrollment
NCT07339384 is an interventional study that assigns participants to a tested intervention. Its 1,010 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which Signatera Genome ultra-sensitive ctDNA blood test is the first listed.
NCT07339384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07339384 about?
NCT07339384 is a clinical study titled "Signatera Assessment in Early-Stage Endometrial Cancer". The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endo...
What is the current status of trial NCT07339384?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,010 participants. The study started on 2026-10. Estimated completion is 2034-10.
What interventions are being tested in trial NCT07339384?
The interventions under investigation include: Signatera Genome ultra-sensitive ctDNA blood test (DEVICE).
Who is sponsoring clinical trial NCT07339384?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07339384's enrollment target sits among peer trials
1,010 106th of 2000 higher than 1,895 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia